TMEM106B Antilichaam

TMEM106B Antibody: Transmembrane protein 106B (TMEM106B) is a single-pass transmembrane protein that is thought to be a novel risk factor for frontotemporal lobar degeneration (FTLD), a group of clinically, pathologically and genetically heterogeneous disorders associated with atrophy in the frontal lobe and temporal lobe of the brain. The actual role of TMEM106B, and that of the closely related protein TMEM106A are still undetermined.

54664

Q9NUM4

NP_060844

Human

Unconjugated

Primary Antibodies

Neuroscience

TMEM106B Antibody is affinity chromatography purified via peptide column.

Cat. No. 1303 - Human Brain Tissue Lysate

1 mg/mL

Predicted species reactivity based on immunogen sequence: Mouse: (100%), Bovine: (87%), Rat: (86%)

TMEM106B Antibody is supplied in PBS containing 0.02% sodium azide.

None

Blue Ice

TMEM106B antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG

This TMEM106B antibody is predicted to have no cross-reactivity to TMEM106A.

TMEM106B

Cat. No. 10-201 - Human Liver Tissue Slide

Transmembrane protein 106B

Homo sapiens

Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 2010; 42:234-9.

Aswathy PM, Jairani PS, and Mathuranath PS. Genetics of frontotemporal lobar degeneration. Ann. Indian Acad. Neurol. 2010; 13 (Suppl 2) :S55-62.

TMEM106B Antibody: Transmembrane protein 106B

ELISA, WB, IHC-P, IF

40254893

Liquid